

Castle Biosciences, Inc. (CSTL)

Market Cap: \$525mil

MARCH 20-21, 2024
MINNEAPOLIS, MILWAUKEE & CHICAGO



Management



Derek Maetzold



Frank Stokes



Camilla Zuckero
VP, IR & Corporate Affairs

Roadshow Host

Mason Carrico, CFA Research Analyst Healthcare: Diagnostics (214) 258-2712

mason.carrico@stephens.com

Space will be limited. Meeting times and itinerary subject to change. To join the trip or to obtain more information, please contact your Stephens sales representative.

About Castle Biosciences, Inc.

Castle Biosciences is a commercial-stage diagnostics company that develops and commercializes prognostic and diagnostic tests for various cancers and diseases in the skin cancer and gastrointestinal market. CSTL's test utilize the genomic information of an individual patient's tumor or biopsy to provide an objective assessment of a patient's specific risk of progression, metastasis, or recurrence of cancer as well as form a more accurate diagnosis of disease.

Stephens

INSTITUTIONAL EQUITIES & RESEARCH

stephens.com

f in y 800-643-9691

© 2024 STEPHENS INC. MEMBER NYSE, SIPC | 111 CENTER STREET, LITTLE ROCK, AR 72201

UNSUBSCRIBE EMAIL PREFERENCES VIEW ONLINE

all any seasily, it does not pupor to be a complete description of the recurlies, materia or developments referred to a life material, the research andly injurispoil; responsible to preparation of this amountment not received correpression for this based on the first werell revenue which includes investment braining revenue. To access current disclosures for the companies in this amountment, the instruction of the companies of the companies of the companies in this amountment, the instruction of the companies o